| アブストラクト | The concurrent use of bortezomib and anticoagulants, including heparin and low molecular weight heparin (LMWH), is increasingly common in the standard clinical management of multiple myeloma. Peripheral neuropathy (PN) is a common and significant toxicity associated with bortezomib. This study aimed to identify and characterize interaction signals for the concomitant use of bortezomib with heparin/LMWH, resulting in PN, using data mining of the FDA Adverse Event Reporting System (FAERS). Adverse event (AE) reports to FAERS were analyzed. We conducted disproportionality analysis to detect PN signals associated with the combined use of bortezomib and heparin/LMWH by estimating reporting odds ratio (ROR) with 95 % confidence interval (CI). Adjusted odds ratios (ORs) were calculated using logistic regression analysis (adjusting for age, sex, and reporting year), and the Omega shrinkage measure method was used to further confirm the findings. Subset data analysis was performed based on the use of heparin and LMWH as a specific drug. From 84,428 AE reports, including 2805 PN reports, the combined use of bortezomib and heparin/LMWH was associated with a lower PN reporting (OR = 1.852, 95 % CI, 1.098-3.126) compared to bortezomib monotherapy (OR = 3.809, 95 % CI, 3.435-4.224), indicating a significant interaction signal. The results remained significant according to the Omega shrinkage measure method. In the subset analyses, an interaction signal was identified for enoxaparin but not for heparin. FAERS data suggest that combining bortezomib and LMWH, specifically enoxaparin, is associated with a reduced risk of PN reporting. No significant interaction was found between bortezomib and heparin. |
|---|
| ジャーナル名 | European journal of pharmacology |
|---|
| Pubmed追加日 | 2025/8/9 |
|---|
| 投稿者 | Zhao, Yibei; Zhang, Sha; Huang, Jing; Yang, Yaji; Ran, Dongzhi; Meng, Long |
|---|
| 組織名 | Department of Histology and Embryology, Third Military Medical University (Army;Medical University), Chongqing, 400038, China.;Department of Pharmacy, Tongji Hospital, School of Medicine, Tongji University,;Shanghai, 200065, China.;Department of Respiratory and Critical Care Medicine, The First Affiliated;Hospital of Chongqing Medical University, Chongqing, 400016, China.;Department of Orthopaedics, The First Affiliated Hospital of Chongqing Medical;University, Chongqing, 400016, China.;Key Laboratory of Biochemistry and Molecular Pharmacology, Department of;Pharmacology, Chongqing Medical University, Chongqing, 400016, China.;Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical;University, Chongqing, 400016, China. Electronic address:;menglong@hospital.cqmu.edu.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40780597/ |
|---|
